N = 31 adults (> 18 years old) with hematologic malignancies undergoing reduced‐intensity allo‐HCT; n = 15 received FOS starting at pre‐transplant conditioning and continuing for 21 days total; n = 16 control patients not receiving FOS; stool and blood samples collected from both groups. The gene discussed is FOS; the disease is hematologic disorder.